PE20030258A1 - Derivados de dolastatina con actividad antitumoral - Google Patents
Derivados de dolastatina con actividad antitumoralInfo
- Publication number
- PE20030258A1 PE20030258A1 PE2002000643A PE2002000643A PE20030258A1 PE 20030258 A1 PE20030258 A1 PE 20030258A1 PE 2002000643 A PE2002000643 A PE 2002000643A PE 2002000643 A PE2002000643 A PE 2002000643A PE 20030258 A1 PE20030258 A1 PE 20030258A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- butyl
- carbamoyl
- metoxy
- butyramide
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical class CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 title 1
- -1 DIALKYLAMINE Chemical class 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical class CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 abstract 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 2
- KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical class O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000003973 alkyl amines Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 150000003974 aralkylamines Chemical class 0.000 abstract 1
- 150000004982 aromatic amines Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A DERIVADOS DE DOLASTATINA 10 QUE TIENEN VARIOS GRUPOS TIO EN LA PARTE DE DOLAPROINA DE FORMULA I DONDE R1, R2, R3 SON H, ALQUILO C1-C4; R4 ES H, ALQUILO OPCIONALMENTE SUSTITUIDO CON HIDROXILO, ALCOXILO, AMINO, DIALQUILAMINO, CARBOXILO, ALCOXICARBONILO, CARBAMOILO, ALQUILCARBONILOXILO, HALOGENO, ALQUENILO, ALQUINILO, CICLOALQUILO C3-C7, ARILO, ENTRE OTROS; R5 ES ALQUILAMINO C1-C6, HIDROXILO, CICLOALQUILAMINO C3-C7, ARILAMINO, ARALQUILAMINO, BENZHIDRAZINO, ENTRE OTROS; n ES 0-2. SON COMPUESTOS PREFERIDOS N-[1-({1-SEC-BUTIL-4-[2-(1-METANOSULFINIL-2-FENETILCARBAMOIL-ETIL)-PIRROLIDIN-1-IL]-2-METOXI-4-OXO-BUTIL}-METIL-CARBAMOIL)-2-METIL-PROPIL]-2-DIMETILAMINO-3-METIL-BUTIRAMIDA; N-[1-({1-SEC-BUTIL-2-METOXI-4-OXO-4-[2-(2-FENETIL-CARBAMOIL-1-FENILSULFANIL-ETIL)-PIRROLIDIN-1-IL]-BUTIL}-METIL-CARBAMOIL)-2-METIL-PROPIL]-2-DIMETILAMINO-3-METIL-BUTIRAMIDA; N-[1-({1-SEC-BUTIL-2-METOXI-4-[2-(1-METILSULFANIL-2-FENETILCARBAMOIL-ETIL)-PIRROLIDIN-1-IL]-4-OXO-BUTIL}-METIL-CARBAMOIL)-2-METIL-PROPIL]-2-DIMETILAMINO-3-METIL-BUTIRAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON DERIVADOS DE DOLASTINA 10, PEPTIDO ANTIMITOTICO POTENTE MUESTRAN ACTIVIDAD ANTITUMORAL MEJORADA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01117410 | 2001-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030258A1 true PE20030258A1 (es) | 2003-03-19 |
Family
ID=8178073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000643A PE20030258A1 (es) | 2001-07-19 | 2002-07-19 | Derivados de dolastatina con actividad antitumoral |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6737409B2 (es) |
| EP (1) | EP1412328B1 (es) |
| JP (1) | JP2004534859A (es) |
| KR (2) | KR20060057652A (es) |
| CN (1) | CN1553897A (es) |
| AR (1) | AR036175A1 (es) |
| AT (1) | ATE341537T1 (es) |
| BR (1) | BR0211289A (es) |
| CA (1) | CA2453987A1 (es) |
| CO (1) | CO5550462A2 (es) |
| DE (1) | DE60215179T2 (es) |
| DK (1) | DK1412328T3 (es) |
| ES (1) | ES2272763T3 (es) |
| GT (1) | GT200200154A (es) |
| HR (1) | HRP20040043A2 (es) |
| HU (1) | HUP0401253A2 (es) |
| IL (1) | IL159890A0 (es) |
| MX (1) | MXPA04000577A (es) |
| MY (1) | MY127718A (es) |
| NO (1) | NO20040198L (es) |
| NZ (1) | NZ530655A (es) |
| PA (1) | PA8551001A1 (es) |
| PE (1) | PE20030258A1 (es) |
| PL (1) | PL367682A1 (es) |
| PT (1) | PT1412328E (es) |
| RU (1) | RU2296750C2 (es) |
| SI (1) | SI1412328T1 (es) |
| UY (1) | UY27388A1 (es) |
| WO (1) | WO2003008378A1 (es) |
| ZA (1) | ZA200400334B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003082268A2 (en) | 2002-03-22 | 2003-10-09 | Eisai Co. Ltd | Hemiasterlin derivatives and uses thereof in the treatment of cancer |
| US7064211B2 (en) | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
| CA2567914A1 (en) * | 2004-06-02 | 2005-12-15 | F. Hoffmann-La Roche Ag | Synthesis of amino-alkoxy-heptanoic alkyl ester |
| AU2005332660A1 (en) | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
| EP1828117A1 (en) * | 2004-12-13 | 2007-09-05 | F. Hoffmann-Roche AG | Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives |
| KR20070086123A (ko) * | 2004-12-13 | 2007-08-27 | 에프. 호프만-라 로슈 아게 | 하나 이상의 돌라스타틴 10 유도체를 포함하는 신규 약학조성물 |
| US20060161076A1 (en) * | 2005-01-06 | 2006-07-20 | Diamics, Inc. | Systems and methods for collection of cell clusters |
| US20060189893A1 (en) * | 2005-01-06 | 2006-08-24 | Diamics, Inc. | Systems and methods for detecting abnormal cells |
| EP1838660A2 (en) * | 2005-01-13 | 2007-10-03 | F. Hoffmann-Roche AG | New one-step synthesis of useful disubstituted amines |
| WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| EP3498289A1 (en) | 2005-07-07 | 2019-06-19 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| SG171682A1 (en) | 2006-05-16 | 2011-06-29 | Aegera Therapeutics Inc | Iap bir domain binding compounds |
| US20080003652A1 (en) * | 2006-06-28 | 2008-01-03 | Hans Iding | Novel enzymatic process for the manufacture of Boc-Dap-Oh priority to related application(s) |
| KR101486615B1 (ko) | 2007-07-16 | 2015-01-28 | 제넨테크, 인크. | 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법 |
| WO2009012256A1 (en) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| RU2553566C2 (ru) | 2008-01-31 | 2015-06-20 | Дженентек, Инк. | АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CA2718942A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| CN102933231B (zh) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | Cd20抗体及其用途 |
| MX340870B (es) | 2010-02-12 | 2016-07-27 | Pharmascience Inc | Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus. |
| US8722629B2 (en) | 2010-06-10 | 2014-05-13 | Seattle Genetics, Inc. | Auristatin derivatives and use thereof |
| US8987209B2 (en) | 2010-09-29 | 2015-03-24 | Seattle Genetics, Inc. | N-carboxyalkyl-auristatin and the use thereof |
| EP2686336B1 (de) * | 2011-03-16 | 2015-05-06 | Seattle Genetics, Inc. | N-carboxyalkyl-auristatine und ihre verwendung |
| EP2714684B1 (en) | 2011-05-27 | 2018-09-05 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| SG195183A1 (en) * | 2011-05-27 | 2013-12-30 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| ES2604766T3 (es) * | 2012-09-20 | 2017-03-09 | Celltrion, Inc. | Derivado de dolastatina-10, procedimiento de producción del mismo y composición de fármaco anticanceroso que contiene el mismo |
| EP3086815B1 (en) | 2013-12-27 | 2022-02-09 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
| WO2016049214A1 (en) | 2014-09-23 | 2016-03-31 | Genentech, Inc. | METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES |
| CN105949277B (zh) * | 2015-05-05 | 2019-03-01 | 成都永泰诺科技有限公司 | 一种抗肿瘤化合物及其用途 |
| CN108779146B (zh) * | 2016-03-29 | 2022-03-18 | 东丽株式会社 | 肽衍生物及其用途 |
| CN109021065B (zh) * | 2017-06-08 | 2021-10-01 | 复旦大学 | 一种制备海兔毒素Dolastatin10的方法 |
| WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2700165B1 (fr) * | 1993-01-07 | 1995-02-17 | Rhone Poulenc Rorer Sa | Dérivés de pyrrolidine, leur préparation et les médicaments les contenant. |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
-
2002
- 2002-07-15 US US10/195,698 patent/US6737409B2/en not_active Expired - Fee Related
- 2002-07-17 ES ES02764710T patent/ES2272763T3/es not_active Expired - Lifetime
- 2002-07-17 HR HR20040043A patent/HRP20040043A2/hr not_active Application Discontinuation
- 2002-07-17 KR KR1020067008692A patent/KR20060057652A/ko not_active Ceased
- 2002-07-17 IL IL15989002A patent/IL159890A0/xx unknown
- 2002-07-17 DK DK02764710T patent/DK1412328T3/da active
- 2002-07-17 UY UY27388A patent/UY27388A1/es not_active Application Discontinuation
- 2002-07-17 PL PL02367682A patent/PL367682A1/xx not_active Application Discontinuation
- 2002-07-17 RU RU2004105145/04A patent/RU2296750C2/ru not_active IP Right Cessation
- 2002-07-17 SI SI200230447T patent/SI1412328T1/sl unknown
- 2002-07-17 AT AT02764710T patent/ATE341537T1/de not_active IP Right Cessation
- 2002-07-17 BR BR0211289-2A patent/BR0211289A/pt not_active IP Right Cessation
- 2002-07-17 MY MYPI20022704A patent/MY127718A/en unknown
- 2002-07-17 KR KR1020047000854A patent/KR100611540B1/ko not_active Expired - Fee Related
- 2002-07-17 EP EP02764710A patent/EP1412328B1/en not_active Expired - Lifetime
- 2002-07-17 CN CNA028177622A patent/CN1553897A/zh active Pending
- 2002-07-17 PT PT02764710T patent/PT1412328E/pt unknown
- 2002-07-17 JP JP2003513938A patent/JP2004534859A/ja active Pending
- 2002-07-17 CA CA002453987A patent/CA2453987A1/en not_active Abandoned
- 2002-07-17 WO PCT/EP2002/007931 patent/WO2003008378A1/en not_active Ceased
- 2002-07-17 HU HU0401253A patent/HUP0401253A2/hu unknown
- 2002-07-17 AR ARP020102678A patent/AR036175A1/es not_active Application Discontinuation
- 2002-07-17 MX MXPA04000577A patent/MXPA04000577A/es active IP Right Grant
- 2002-07-17 NZ NZ530655A patent/NZ530655A/en unknown
- 2002-07-17 DE DE60215179T patent/DE60215179T2/de not_active Expired - Fee Related
- 2002-07-18 GT GT200200154A patent/GT200200154A/es unknown
- 2002-07-18 PA PA20028551001A patent/PA8551001A1/es unknown
- 2002-07-19 PE PE2002000643A patent/PE20030258A1/es not_active Application Discontinuation
-
2004
- 2004-01-15 ZA ZA2004/00334A patent/ZA200400334B/en unknown
- 2004-01-16 NO NO20040198A patent/NO20040198L/no not_active Application Discontinuation
- 2004-01-20 CO CO04003736A patent/CO5550462A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030258A1 (es) | Derivados de dolastatina con actividad antitumoral | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| PE20040522A1 (es) | Derivados de diarilurea dependientes de la cinasa de proteina | |
| HUP0301573A2 (hu) | Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| ES2128092T3 (es) | Derivados de anilina. | |
| ES2093367T3 (es) | Derivados de quinazolina. | |
| FR2743562B1 (fr) | Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant | |
| HUP0203803A2 (hu) | Neurodegenerációs betegségek kezelésére alkalmazható pirido-pirimidinon-származékok | |
| BR0215157A (pt) | Cis-2,4,5-trifenil-imidazolinas e seu uso no tratamento de tumores | |
| LU92146I2 (fr) | Dasatinib et ses sels pharmaceutiquement acceptables | |
| EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
| GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
| CY1112084T1 (el) | Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3 | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| AR024145A1 (es) | Derivados de 5-fenil-pirimidina | |
| NO308248B1 (no) | Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat | |
| AR008177A1 (es) | Nuevas bisindolilmaleimidas, sales de las mismas, procesos para su preparacion intermediarios, su uso para la fabricacion de medicamentos, metodode tratamiento y composicion farmaceutica. | |
| CL2004001050A1 (es) | Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul | |
| CY1106544T1 (el) | Μεθοδος συνθεσεως υπερινδοπριλης και τα φαρμακευτικως αποδεκτα αλατα αυτης | |
| ATE422362T1 (de) | Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose | |
| NO20052229L (no) | Basiske estere av fettalkoholer og deres anvendelse som antiinfammatoriske eller immunstimulerende midler | |
| DE602004006379D1 (de) | Benzthiazol-3 oxide zur behandlung von proliferativen störungen | |
| DE60014343D1 (de) | N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten | |
| EA200501900A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| EA200501925A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |